CRBP - コ―バス・ファ―マシュ―ティカルズ (Corbus Pharmaceuticals Holdings Inc.) コ―バス・ファ―マシュ―ティカルズ

 CRBPのチャート


 CRBPの企業情報

symbol CRBP
会社名 Corbus Pharmaceuticals Holdings Inc (コ―バス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コールバス・ファーマシューティカルズ・ホールディングス(Corbus Pharmaceuticals Holdings Inc.)は臨床段階の製薬会社である。同社は希少・慢性・深刻炎症性及び線維性疾患を治療するための治療薬の開発・商品化に焦点を当てる。同社は希少な生命を脅かす炎症性線維症疾患の治療薬の開発・商品化を通じて事業を運営する。同社の製品であるlenabasumは慢性炎症を解消し、線維化過程を止めるように設計された合成経口エンドカンナビノイド模倣薬である。lenabasumは内因性経路を活性化することによって炎症を解消し、線維化を停止させるように作用する専門化されたプロ解消脂質メディエーター(SPM)の生産を促進する。同社は全身性硬化症、嚢胞性線維症、びまん性皮膚疾患、皮膚優性皮膚筋炎及び全身性エリテマトーデス(SLE)の4つの疾患を治療するためのlenabasumを開発する。   コ―バス・ファ―マシュ―ティカルズは炎症性線維症の治療薬の開発と商品化に焦点を置く米国のバイオ医薬品会社。第2相臨床試験を行う「リスナブ」は嚢胞性線維症と硬皮症の治療用の経口抗炎症剤。「リスナブ」はカンナビノイド受容体(CB2)を活性化し、抗炎性物質の放出を促進するとともに、炎症性物質の放出とサイトカインの分泌を抑制。   Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.
本社所在地 500 River Ridge Drive Norwood MA 02062 USA
代表者氏名 Mark A. Tepper マークA.テッパー
代表者役職名 President Chief Scientific Officer
電話番号 +1 617-963-0103
設立年月日
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 47人
url www.corbuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/crbp
adr_tso
EBITDA EBITDA(百万ドル) -41.67992
終値(lastsale) 6.79
時価総額(marketcap) 388429351.1
時価総額 時価総額(百万ドル) 396.43820
売上高 売上高(百万ドル) 2.60040
企業価値(EV) 企業価値(EV)(百万ドル) 331.84536
当期純利益 当期純利益(百万ドル) -41.42403
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Corbus Pharmaceuticals Holdings Inc revenues increased 10% to $1.8M. Net loss increased 61% to $23.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 65% to $20M (expense) General and administrative increase of 42% to $6M (expense).

 CRBPのテクニカル分析


 CRBPのニュース

   Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors  2021/08/03 12:01:27 MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors MarketWatch
   Explore Volume Patterns For Some Important Insights: Marvell Technology, Inc. (NASDAQ:MRVL), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)  2021/08/01 22:41:05 Stock Equity
Marvell Technology, Inc. (NASDAQ:MRVL) with the stream of 0.33% also noticed, India Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) encountered a rapid change of -2.14% in the last hour of Fridays trading The post Explore Volume Patterns For Some Important Insights: Marvell Technology, Inc. (NASDAQ:MRVL), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) appeared first on Stocks Equity .
   Global Medicinal Cannabis Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: GreenWich, Manitoba Harvest, Bausch Health, Abbvie, Aphria, Insys Therapeutics, Botanical Genetics, Corbus Pharmaceuticals, Tilray, Phytokann, Jinzhou Qiaopai Biotech  2021/07/23 23:12:49 Jumbo News
The report on Global Medicinal Cannabis Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
   Hot Stock in Focus: Delta Air Lines, Inc. (NYSE:DAL), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)  2021/07/20 22:23:34 Stock Equity
Delta Air Lines, Inc. (NYSE:DAL) with the stream of 4.89% also noticed, India Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) encountered a rapid change of 1.76% in the last hour of Tuesdays The post Hot Stock in Focus: Delta Air Lines, Inc. (NYSE:DAL), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) appeared first on Stocks Equity .
   Have a sight on this: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Bristol-Myers Squibb Company (NYSE:BMY)  2021/07/18 23:05:43 Stock Equity
Corbus Pharmaceuticals Holdings, Inc. (CRBP) with the stream of -2.63% also noticed, India Bristol-Myers Squibb Company (BMY) encountered a rapid change of -0.19% in the last hour of trading session. The post Have a sight on this: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Bristol-Myers Squibb Company (NYSE:BMY) appeared first on Stocks Equity .
   Stock Jumping on Abnormally High Volume: Clean Energy Fuels Corp. (NASDAQ:CLNE), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)  2021/07/14 21:09:34 Stock Equity
Clean Energy Fuels Corp. (CLNE) with the stream of -5.58% also noticed, India Corbus Pharmaceuticals Holdings, Inc. (CRBP) encountered a rapid change of -0.31% in the last hour of Wednesdays The post Stock Jumping on Abnormally High Volume: Clean Energy Fuels Corp. (NASDAQ:CLNE), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) appeared first on Stocks Equity .
   Explore Volume Patterns For Some Important Insights: NortonLifeLock Inc. (NASDAQ:NLOK), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)  2021/07/11 21:01:49 Stock Equity
NortonLifeLock Inc. (NLOK) with the stream of 1.65% also noticed, India Corbus Pharmaceuticals Holdings, Inc. (CRBP) encountered a rapid change of 3.61% in the last hour of Fridays trading session. The post Explore Volume Patterns For Some Important Insights: NortonLifeLock Inc. (NASDAQ:NLOK), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) appeared first on Stocks Equity .
   Highly Unusual Volume Spikes: Acasti Pharma Inc. (NASDAQ:ACST), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)  2021/07/07 22:19:28 Stock Equity
Acasti Pharma Inc. (NASDAQ:ACST) with the stream of -4.72% also noticed, India Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) encountered a rapid change of 1.78% in the last hour of Wednesdays trading The post Highly Unusual Volume Spikes: Acasti Pharma Inc. (NASDAQ:ACST), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) appeared first on Stocks Equity .
   New cannabinoid CB2 receptor agonists discovered at Corbus Pharmaceuticals  2021/07/02 13:58:13 BioWorld
   Corbus Pharmaceuticals Expands Pipeline with Two New mAbs  2021/06/30 20:43:00 BioPharm
Corbus Pharmaceuticals Holdings has expanded its therapeutics pipeline with the addition of two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor (TGF).
   Oasis Midstream Partners, Corbus Pharmaceuticals among premarket losers'' pack  2021/06/25 12:06:19 Seeking Alpha
   Corbus shares fall as autoimmune drug fails another late-stage trial  2021/06/24 16:51:35 Business Journals
Shares of Corbus Pharmaceuticals dropped Thursday on the news that its drug lenabasum has failed to effectively treat dermatomyositis in a late-stage trial. It''s the third late-stage trial failure in a year for the same drug.
   Corbus Says DETERMINE Phase 3 Study Of Lenabasum Did Not Meet Primary Endpoint - Quick Facts  2021/06/24 12:32:58 Business Insider Markets
(RTTNews) - Immunology company Corbus Pharmaceuticals Holdings Inc. (CRBP) announced Thursday topline results from the Phase 3 DETERMINE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis. The study did not meet its primary endpoint of Total Improvement Score (TIS) at Week 28. Higher TIS values
   Corbus Pharma hurt by setback in late-stage trial for rare autoimmune disease  2021/06/24 12:32:41 Seeking Alpha
   Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis  2021/06/24 12:05:00 Intrado Digital Media
Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, today announced topline results from the Phase 3 D ETER M INE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コ―バス・ファ―マシュ―ティカルズ CRBP Corbus Pharmaceuticals Holdings Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)